Oral Candidiasis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ORL005 MIFTS: 55	Oral Candidiasis Categories: Gastrointestinal diseases, Infectious diseases, Oral diseases, Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Oral Candidiasis

MalaCards integrated aliases for Oral Candidiasis:

Name: Oral Candidiasis ¹¹ ⁵³ ¹⁴ ¹⁶ ⁷¹ ⁷⁵

Thrush ¹¹ ⁷⁵ ²

Candidiasis of Mouth ¹¹

Candidiasis, Oral ⁴³

Oral Moniliasis ¹¹

Equine Thrush ⁷¹

Thrush, Oral ¹¹

Candidiasis ⁷¹

Oral Thrush ⁶³

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Oral diseases Gastrointestinal diseases Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Certain infectious and parasitic diseases

Mycoses

Candidiasis

Candidiasis, unspecified

External Ids:

Disease Ontology ¹¹ DOID:14262

ICD9CM ³⁴ 112.0

MeSH ⁴³ D002180

NCIt ⁴⁹ C28137

SNOMED-CT ⁶⁸ 187006006

ICD10 ³¹ B37.9

EFO ¹⁶ EFO_0007406

UMLS ⁷¹ C0006840 C0006849 C1299921

Sources

Summaries for Oral Candidiasis

PubMed Health : ⁶³ Oral thrush: Oral thrush is a condition that can be difficult to recognize at first. It is rarely dangerous and not necessarily painful, but can be very unpleasant and greatly affect your quality of life. Oral thrush is caused by types of yeast fungus called Candida that live in the mucous membranes lining your mouth. Its medical name “oral candidiasis” is taken from this fungus. Oral thrush is most often caused by a type of Candida fungus called Candida albicans. Most people have small amounts of Candida on the mucous linings of their mouth without it causing any noticeable problems. But given the right conditions, the fungus can start reproducing very quickly. This often affects people who have serious diseases, and it can also be a side effect of certain types of treatment.

MalaCards based summary: Oral Candidiasis, also known as thrush, is related to candida glabrata and denture stomatitis, and has symptoms including oral manifestations An important gene associated with Oral Candidiasis is DEFB4A (Defensin Beta 4A), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Innate Immune System. The drugs Fluticasone and Nystatin have been mentioned in the context of this disorder. Affiliated tissues include tongue, skin and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and immune system

CDC: ² Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems.1 Sometimes, Candida can multiply and cause an infection if the environment inside the mouth, throat, or esophagus changes in a way that encourages fungal growth. Candidiasis in the mouth and throat is also called "thrush" or oropharyngeal candidiasis. Candidiasis in the esophagus (the tube that connects the throat to the stomach) is called esophageal candidiasis or Candida esophagitis. Esophageal candidiasis is one of the most common infections in people living with HIV/AIDS

Disease Ontology: ¹¹ A candidiasis that involves fungal infection of the mucous membrane of the mouth by Candida species, which is characterized by thick white or cream-colored deposits on inflamed mucosal membranes.

Wikipedia ⁷⁵ Oral candidiasis: Oral candidiasis, also known as oral thrush among other names, is candidiasis that occurs in the mouth.... more...

Thrush: Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Sources

Related Diseases for Oral Candidiasis

Diseases related to Oral Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)

#	Related Disease	Score	Top Affiliating Genes
1	candida glabrata	31.1	SKAP2 HTN3 APCS
2	denture stomatitis	31.1	ECE1 DEFB4A CLEC7A
3	candidiasis	30.9	SKAP2 LTF IL17RA IL17F IL17A HTN3
4	angular cheilitis	30.9	IL17A CD4 AIRE
5	sjogren syndrome	30.7	LTF CCR6 B2M
6	immune deficiency disease	30.7	IRF8 IL17A CD4 CCR6 B2M APCS
7	psoriasis 11	30.5	IL17RA IL17F IL17A
8	common cold	30.4	IL17A CD4 CCR6
9	viral infectious disease	30.3	IL17A CD4 CCR6 B2M
10	t cell deficiency	30.3	IL17A CD4 CCR6
11	exanthem	30.3	IL17A CD4 CCR6
12	severe covid-19	30.3	IL17A CD4 CCR6
13	vaginitis	30.2	IL17A DEFB4A CD4 CCR6
14	mucormycosis	30.2	CLEC7A CD4 CCR6 CARD9
15	pneumocystosis	30.1	IL17A CLEC7A CD4 CCR6 CARD9
16	human cytomegalovirus infection	30.1	IL17A CD4 CCR6
17	anterior uveitis	30.1	IL17A CD4 CCR6
18	salmonellosis	30.1	IL17A CD4 CCR6
19	psoriasis	30.0	IL17RA IL17F IL17A DEFB4A CD4 CCR6
20	seborrheic dermatitis	30.0	IL17A DEFB4A CD4 CCR6
21	blepharitis	30.0	LTF IL17A CD4 CCR6
22	bacterial pneumonia	30.0	IL17A DEFB4A CD4 CCR6
23	behcet syndrome	30.0	IRF8 IL17F IL17A CD4 CCR6
24	autoimmune disease	29.9	IL17F IL17A CCR6 B2M AIRE
25	cryptococcal meningitis	29.9	IL17A CLEC7A CLEC6A CD4 CCR6
26	spondyloarthropathy 1	29.9	IL17F IL17A CD4 CCR6
27	histoplasmosis	29.8	CLEC7A CLEC6A CD4 CCR6
28	crohn's disease	29.8	LTF IL17F IL17A CD4 CCR6
29	esophageal candidiasis	29.8	IL17A CLEC7A CD4 CCR6 CARD9 AIRE
30	severe combined immunodeficiency	29.8	IL17A IKBKB CD4 CCR6 AIRE
31	combined immunodeficiency	29.8	IL17A IKBKB CD4 CCR6 AIRE
32	cryptococcosis	29.7	IL17A CLEC7A CLEC6A CD4 CCR6 CARD9
33	chronic mucocutaneous candidiasis	29.5	IL17RA IL17F IL17A CLEC7A CLEC6A CD4
34	tinea pedis	29.4	IL17A DEFB4A CLEC7A CLEC6A CD4 CCR6
35	skin disease	29.3	IL17RA IL17F IL17A IKBKB DEFB4A CD4
36	vulvovaginal candidiasis	29.2	IL17RA IL17A ECE1 CLEC7A CLEC6A CCR6
37	dermatophytosis	29.1	IL17F IL17A DEFB4A CLEC7A CLEC6A CD4
38	autoimmune polyendocrine syndrome	29.1	IL17RA IL17F IL17A CLEC7A CD4 CCR6
39	autoimmune polyendocrine syndrome type 1	29.1	IL17RA IL17F IL17A CLEC7A CD4 CCR6
40	fungal infectious disease	28.9	IL17RA IL17F IL17A ECE1 DEFB4A CLEC7A
41	severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative	11.1
42	immunodeficiency 104	11.1
43	median rhomboid glossitis	11.1
44	immunodeficiency 32b	11.1
45	t-cell immunodeficiency, congenital alopecia, and nail dystrophy	11.1
46	immunodeficiency 15a	11.1
47	acquired immunodeficiency syndrome	10.6
48	human immunodeficiency virus type 1	10.6
49	stomatitis	10.6
50	leukoplakia	10.5

Comorbidity relations with Oral Candidiasis via Phenotypic Disease Network (PDN): (show all 35)

Graphical network of the top 20 diseases related to Oral Candidiasis:

Sources

Symptoms & Phenotypes for Oral Candidiasis

UMLS symptoms related to Oral Candidiasis:

oral manifestations

GenomeRNAi Phenotypes related to Oral Candidiasis according to GeneCards Suite gene sharing:

²⁵ (show all 22)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	9.72	DEFB4A
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-14	9.72	CD4
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-147	9.72	CD4
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-148	9.72	DEFA1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-153	9.72	DEFB4A
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-160	9.72	CD4
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-165	9.72	DEFB4A
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-173	9.72	IKBKB
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-176	9.72	DEFA1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-178	9.72	DEFA1
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-185	9.72	IKBKB
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-19	9.72	CD4
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	9.72	IKBKB
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-200	9.72	DEFB4A
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-212	9.72	DEFA1
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	9.72	CD4 DEFA1
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-38	9.72	IKBKB
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	9.72	IKBKB
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-54	9.72	DEFA1 DEFB4A IKBKB
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-59	9.72	IKBKB
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.72	DEFA1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.72	IKBKB

MGI Mouse Phenotypes related to Oral Candidiasis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	9.89	AIRE APCS B2M CARD9 CCR6 CD4
2	digestive/alimentary	MP:0005381	9.76	AIRE B2M CD4 CLEC7A ECE1 IKBKB
3	hematopoietic system	MP:0005397	9.55	AIRE APCS B2M CARD9 CCR6 CD4

Sources

Drugs & Therapeutics for Oral Candidiasis

PubMed Health treatment related to Oral Candidiasis: ⁶³

Oral thrush can be treated with antimycotics. These are available as drugs that produce either a topical (local) or a systemic (throughout the whole body) effect. Medication that acts in both ways is also an option. The type of medication that is best suited for someone with a weakened immune system will depend on their individual situation.

Drugs for Oral Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Fluticasone

Approved, Experimental

Phase 4

90566-53-3

4659387 5311101

Nystatin

Approved, Vet_approved

Phase 4

1400-61-9

11953884

Amphotericin B

Approved, Investigational

Phase 4

1397-89-3

5280965

Voriconazole

Approved

Phase 4

137234-62-9

71616

Dequalinium

Approved, Investigational

Phase 4

6707-58-0

2993

Terconazole

Approved

Phase 4

67915-31-5

441383

Clindamycin

Approved, Vet_approved

Phase 4

18323-44-9, 24729-96-2

29029

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

3640 5754

Tinidazole

Approved, Investigational

Phase 4

19387-91-8

5479

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Posaconazole

Approved, Investigational, Vet_approved

Phase 4

171228-49-2

147912

Fluticasone-Salmeterol Drug Combination

Phase 4

Bronchodilator Agents

Phase 4

Adrenergic beta-Agonists

Phase 4

Anti-Asthmatic Agents

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic Agents

Phase 4

Neurotransmitter Agents

Phase 4

Anti-Allergic Agents

Phase 4

Xhance

Phase 4

Sympathomimetics

Phase 4

Salmeterol Xinafoate

Phase 4

94749-08-3

Anti-Infective Agents, Local

Phase 4

Cytochrome P-450 CYP3A Inhibitors

Phase 4

Anti-Bacterial Agents

Phase 4

Ionophores

Phase 4

Antiprotozoal Agents

Phase 4

Antiparasitic Agents

Phase 4

Liposomal amphotericin B

Phase 4

Antibiotics, Antitubercular

Phase 4

Anti-Inflammatory Agents

Phase 4

Clindamycin phosphate

Phase 4

32603

Clindamycin palmitate

Phase 4

Liver Extracts

Phase 4

Hydrocortisone 17-butyrate 21-propionate

Phase 4

Acidophilus

Phase 4

Echinocandins

Phase 4

Metronidazole

Approved

Phase 3

443-48-1, 69198-10-3

4173

Ketoconazole

Approved, Investigational

Phase 3

65277-42-1, 142128-57-2

47576 3823 638701

Gentian violet cation

Approved

Phase 3

14426-25-6, 7438-46-2

3468 11057

Itraconazole

Approved, Investigational

Phase 3

84625-61-6

55283

Isavuconazole

Approved, Investigational

Phase 3

241479-67-4

21937662

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Tetracycline

Approved, Vet_approved, Withdrawn

Phase 3

60-54-8

5353990

Simethicone

Approved

Phase 3

8050-81-5

Ibrexafungerp

Approved, Investigational

Phase 3

1207753-03-4

75163792

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Interventional clinical trials:

(show top 50) (show all 272)

#	Name	Status	NCT ID	Phase	Drugs
1	A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma	Unknown status	NCT00235053	Phase 4	fluticasone/salmeterol DISKUS 250/50
2	Diagnosis of Pulmonary Candidiasis	Unknown status	NCT00537888	Phase 4	fluconazole
3	Fluconazole Prophylaxis of Thrush in AIDS	Completed	NCT00001542	Phase 4	fluconazole
4	Oral Candidiasis in HIV Infected Individuals in Tanzania	Completed	NCT00553137	Phase 4	fluconazole
5	A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis	Completed	NCT00000951	Phase 4	Fluconazole
6	Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis	Completed	NCT02242695	Phase 4	Fluomizin vaginal tablets;Canesten vaginal tablets
7	CRITIC: Phase II Pilot Multicenter Study on Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) at 2 mg/kg/Day in the Treatment of Candidemia and Invasive Candidiasis in Non-Neutropenic Patients	Completed	NCT00670657	Phase 4	AmBisome
8	Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients	Completed	NCT00548262	Phase 4	Anidulafungin;Voriconazole
9	Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis.	Completed	NCT02248506	Phase 4
10	A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting	Completed	NCT00520234	Phase 4	Caspofungin;Normal Saline
11	Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis	Completed	NCT00496197	Phase 4	Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
12	Pharmacokinetics and Optimal Dosage of Caspofungin in Critically Ill Patients With Suspected Invasive Candidiasis	Completed	NCT01994096	Phase 4	Caspofungin
13	Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE	Completed	NCT00194324	Phase 4	Miconazole nitrate
14	A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Micafungin (50 mg/Vial) After Intravenous Infusion of 50 mg Micafungin in Healthy Volunteers Under Fasting Conditions	Completed	NCT05496725	Phase 4	Micafungin
15	A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe	Completed	NCT02180100	Phase 4	Terconazole Vaginal Suppository;Fluconazole
16	An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis	Completed	NCT02180828	Phase 4	Clotrimazole vaginal tablet;Fluconazole
17	Pharmacokinetics of Micafungin in Patients of Intensive Care Units	Completed	NCT02164890	Phase 4
18	Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis	Completed	NCT00702507	Phase 4	0.25 % Miconazole Nitrate Ointment
19	Effectiveness and Safety of Daktacort Feminine Care Cream in the Treatment of Vulvar Candidiasis	Completed	NCT01769339	Phase 4	Miconazole plus Hydrocortisone
20	A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients	Completed	NCT01734525	Phase 4	Anidulafungin
21	Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis	Completed	NCT02860845	Phase 4	Antibiotic (Clindamycin);Antifungal (Clotrimazole)
22	Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration (FOLIA)	Completed	NCT04122560	Phase 4	Fluconazole 200mg tab;Fluconazole 2 MG/ML
23	An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection	Completed	NCT00647907	Phase 4	Voriconazole
24	Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk	Completed	NCT00001107	Phase 4	Fluconazole;AmBisome
25	A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections	Completed	NCT03839875	Phase 4	Gynomax® XL Vaginal Ovule
26	The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients	Completed	NCT01495039	Phase 4	Nystatin
27	Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection	Recruiting	NCT03717623	Phase 4	Posaconazole pharmacokinetics
28	A Prospective, Case-controlled Randomized Study of Human Reproductive Tract Active Lactobacillus in Adjuvant Treatment of Recurrent Vulvovaginal Candidiasis.	Recruiting	NCT04699240	Phase 4	clotrimazole vaginal tablets;Clotrimazole vaginal tablets+ Lactobacillus
29	A Randomized Controlled Trial to Compare the Efficacy of a Medical Grade Honey Formulation (L-Mesitran®) and Fluconazol (Diflucan®) for the Treatment of Recurrent Vulvovaginal Candidiasis	Not yet recruiting	NCT04626258	Phase 4	Fluconazole
30	Multicenter Study to Compare Two Diagnostic Tests (1,3-β-D-glucan vs Blood Culture) in Critically Ill Patients With Suspected Invasive CAndidiasis Hospitalized in Internal Medicine Wards and Who Are Currently Timely Treated With Echinocandin (Micafungin)	Terminated	NCT03906916	Phase 4	Micafungin
31	A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment)	Terminated	NCT01982071	Phase 4	Micafungin
32	A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp	Terminated	NCT02646800	Phase 4	Micafungin
33	A Randomized Comparative Study of Fluconazole Versus Micafungin for the Treatment of Candida Bloodstream Infection in Non-Neutropenic Patients	Withdrawn	NCT00304772	Phase 4	Fluconazole;Micafungin
34	Ketoconazole In Situ Gel Versus Terconazole Cream for Treatment of Vaginal Candidiasis	Unknown status	NCT03473418	Phase 3	Ketoconazole;Terconazole
35	"A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis ".	Unknown status	NCT02635438	Phase 3	Unique Pharmaceutical Laboratories, India;Roxane Laboratories Inc., USA
36	Fluconazole Versus Micafungin in Neonates With Suspected or Culture-proven Candidiasis: a Randomized Pharmacokinetic and Safety Study (TINN Project - Treat Infections iN Neonates)	Unknown status	NCT02145832	Phase 2, Phase 3	Fluconazole;Micafungin
37	Prospective Multicentre Randomized Double-blind Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis	Unknown status	NCT03580733	Phase 3	caspofungin antifungal therapy
38	Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis)	Unknown status	NCT00889356	Phase 3	Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
39	A Phase 3, Randomized, Double-Blind, Comparative Trial of Two Dosing Regimens of Micafungin (FK463) Versus Caspofungin for the Treatment of Esophageal Candidiasis	Completed	NCT00665639	Phase 3	micafungin;caspofungin
40	A Phase 3, Randomized, Double-Blind, Comparative Trial of Micafungin Versus Fluconazole for the Treatment of Esophageal Candidiasis	Completed	NCT00666185	Phase 3	Micafungin;Fluconazole
41	A Comparison of Gentian Violet Mouth Washes, Nystatin Drops and Ketoconazole Tabs in the Treatment of Oropharyngeal Candidiasis	Completed	NCT00128323	Phase 3	Gentian violet 1% solution;Gentian violet 0.00165% solution;Nystatin solution
42	Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients	Completed	NCT00002446	Phase 3	Posaconazole;Fluconazole
43	A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2	Completed	NCT00001812	Phase 3	Nystatin
44	Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People	Completed	NCT02818803	Phase 3	Miconazole
45	A Prospective Randomized, Blinded Parallel Group Study of Clotrimazole Troches vs. Mycelex® Troches (10 mg Troche Five Times a Day for 14 Days) in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis	Completed	NCT02184351	Phase 3	Roxanes's clotrimazole troches;Mycelex® troches
46	A Non-comparative, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate (MK-0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults	Completed	NCT00635648	Phase 3	caspofungin acetate
47	Phase 3, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules vs Fluconazole and Placebo in Treatment of Acute Vulvovaginal Candidiasis in Subjects With Recurrent Vulvovaginal Candidiasis	Completed	NCT03840616	Phase 3	Oteseconazole (VT-1161) 150mg capsule;Fluconazole 150mg capsule;Placebo
48	A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections	Completed	NCT00413218	Phase 3	Isavuconazole;Caspofungin;Voriconazole
49	Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations	Completed	NCT00689338	Phase 3	Anidulafungin;Fluconazole;Voriconazole
50	Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo.	Completed	NCT02251093	Phase 3	Lcr Regenerans;Placebo

Search NIH Clinical Center for Oral Candidiasis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Chlorhexidine

chlorhexidine gluconate

Clotrimazole

Fluconazole

Flucytosine

Itraconazole

Ketoconazole

NYSTATIN PWDR

Cochrane evidence based reviews: candidiasis, oral

Sources

Genetic Tests for Oral Candidiasis

Sources

Anatomical Context for Oral Candidiasis

Organs/tissues related to Oral Candidiasis:

MalaCards : Tongue, Skin, Liver, Myeloid, Bone Marrow, Kidney, Salivary Gland

Sources

Publications for Oral Candidiasis

Articles related to Oral Candidiasis:

(show top 50) (show all 3561)

#	Title	Authors	PMID	Year
1	Differential expression of secretory aspartyl proteinase genes (SAP1-10) in oral Candida albicans isolates with distinct karyotypes. ⁵³ ⁶²	Tavanti A...Senesi S	15472333	2004
2	[Development of murine experimental model for candidiasis and its application]. ⁵³ ⁶²	Abe S	15550920	2004
3	Susceptibility of Candida dubliniensis to salivary histatin 3. ⁵³ ⁶²	Fitzgerald DH...O'Connell BC	12499171	2003
4	Nonspecific secretory immunity in HIV-infected patients with oral candidiasis. ⁵³ ⁶²	Bard E...Meillet D	12439202	2002
5	Immunohistochemical study on expression of alpha-defensin and beta-defensin-2 in human buccal epithelia with candidiasis. ⁵³ ⁶²	Sawaki K...Sugahara T	11936455	2002
6	Increased serum and salivary immunoglobulins against Candida albicans in HIV-infected patients with oral candidiasis. ⁵³ ⁶²	Drobacheff C...Meillet D	11506465	2001
7	Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways. ⁵³ ⁶²	Edgerton M...Bruenn JA	11083633	2000
8	Complete response of severe, refractory oral candidiasis to mouthwash containing lactoferrin and lysozyme. ⁵³ ⁶²	Masci JR	11089630	2000
9	In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. ⁵³ ⁶²	Naglik JR...Agabian N	10225911	1999
10	Predictive value of viral load and other markers for progression to clinical AIDS after CD4+ cell count falls below 200/microL. SEROCO & HEMOCO Study Group. ⁵³ ⁶²	Carre N...Meyer L	9839750	1998
11	Age, gender, and other predictors of the wasting syndrome among HIV-1-infected injecting drug users. ⁵³ ⁶²	Sorkin JD...Graham NM	7742405	1995
12	Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. ⁵³ ⁶²	Zangerle R...Fuchs D	7932082	1994
13	Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. ⁵³ ⁶²	Coates RA...Shepherd FA	1569421	1992
14	A near-complete and time-calibrated phylogeny of the Old World flycatchers, robins and chats (Aves, Muscicapidae). ⁶²	Zhao M...Kimball RT	36265831	2023
15	Development, optimization, and evaluation of a nanostructured lipid carrier of sesame oil loaded with miconazole for the treatment of oral candidiasis. ⁶²	Hosny KM...Kurakula M	35014929	2022
16	In vitro inhibition of a multispecies oral cavity biofilm by Syzygium aromaticum essential oil. ⁶²	Guimaraes Silva Vasconcelos P...Maria Melo de Brito Costa E	34633113	2022
17	Severe congenital neutropenia caused by ELANE gene mutation: A case report and literature review. ⁶²	Wang J...Yang Z	36343040	2022
18	Distribution and antifungal susceptibility profiles of Candida species isolated from people living with HIV/AIDS in a public hospital in Goiânia, GO, Brazil. ⁶²	Freitas VAQ...Silva MDRR	36371517	2022
19	The relation between serum levels of interleukin 10 and interferon-gamma with oral candidiasis in type 2 diabetes mellitus patients. ⁶²	Halimi A...Sarraf SJ	36443718	2022
20	Species distribution and susceptibility profiles of oral candidiasis in hematological malignancy and solid tumor patients. ⁶²	Nasri E...Fakhim H	36378415	2022
21	Responses of Hermit Thrush (Catharus guttatus) males to conspecific playback with typical and atypical syntactical patterns. ⁶²	Nesbitt M...Roach S	36243379	2022
22	Pressure for rapid and accurate mate recognition promotes avian-perceived plumage sexual dichromatism in true thrushes (genus: Turdus). ⁶²	Luro AB...Hauber ME	36196886	2022
23	Non-invasive elevation of circulating corticosterone increases the rejection of foreign eggs in female American robins (Turdus migratorius). ⁶²	Turner AM...Hauber ME	36395578	2022
24	Current Drug Delivery Strategies for Buccal Cavity Ailments using Mouth Dissolving Wafer Technology: A Comprehensive Review on the Present State of the Art. ⁶²	Jana BK...Mazumder B	36443976	2022
25	High-throughput assay for effect screening of amphotericin B and bioactive components on filamentous Candida albicans. ⁶²	Haslene-Hox H...Sletta H	35947058	2022
26	Pediatric lichen planus: A single-center retrospective review of 26 patients with follow up. ⁶²	Mohandesi NA...Davis DMR	36373243	2022
27	Unexpected Candidal Hyphae in Oral Mucosa Lesions-A Clinico-Pathological Study. ⁶²	Edel J...Zlotogorski-Hurvitz A	36290044	2022
28	Frequency of Candida spp. in the Oral Cavity of Asymptomatic Preschool Mexican Children and Its Association with Nutritional Status. ⁶²	Pinto-Almazan R...Martinez-Herrera E	36291446	2022
29	White Tongue Because of Uremic Stomatitis as a Sign of Advanced Kidney Disease. ⁶²	Hasselfeld K...Blanchette E	36168856	2022
30	Inferring Therapeutic Targets in Candida albicans and Possible Inhibition through Natural Products: A Binding and Physiological Based Pharmacokinetics Snapshot. ⁶²	Basharat Z...Zehra M	36362898	2022
31	Receptor-kinase EGFR-MAPK adaptor proteins mediate the epithelial response to Candida albicans via the cytolytic peptide toxin, candidalysin. ⁶²	Ponde NO...Naglik JR	36037968	2022
32	Important Roles and Potential Uses of Natural and Synthetic Antimicrobial Peptides (AMPs) in Oral Diseases: Cavity, Periodontal Disease, and Thrush. ⁶²	Luong AD...Luong JHT	36278644	2022
33	Palliative Treatment of Esophageal Cancer Using Calcium Electroporation. ⁶²	Egeland C...Achiam MP	36358702	2022
34	Bioinformatics analysis to identify intersection genes, associated pathways and therapeutic drugs between COVID-19 and Oral candidiasis. ⁶²	Yang L...Liu Z	36214307	2022
35	Passerine birds. ⁶²	Schmitt CJ...Edwards SV	36283383	2022
36	Impact of enteral immunonutrition on infectious complications and immune and inflammatory markers in cancer patients undergoing chemotherapy: A systematic review of randomised controlled trials. ⁶²	Miller LJ...Calder PC	36067585	2022
37	Nystatin Effectiveness in Oral Candidiasis Treatment: A Systematic Review & Meta-Analysis of Clinical Trials. ⁶²	Rai A...Lapinska B	36362833	2022
38	Biofilm formation of Candida isolates from xerostomic post-radiotherapy head and neck cancer patients. ⁶²	Leerahakan P...Lam-Ubol A	35839697	2022
39	In vitro antimicrobial effects of chitosan on microcosm biofilms of oral candidiasis. ⁶²	Araujo HC...Monteiro DR	35914573	2022
40	Multiple Post-SARS-COV2 Infectious Complications in Kidney Transplant Recipient. ⁶²	Grzejszczak P...Kurnatowska I	36295531	2022
41	Curcumin nanoparticles: the topical antimycotic suspension treating oral candidiasis. ⁶²	Anwar SK...Essawy MM	36100802	2022
42	Oral candidiasis in patients with haematological diseases: Diagnosis through clinical and cytopathological examinations. ⁶²	Pereira FGA...Junior AS	35603463	2022
43	Comparison between two antimicrobial photodynamic therapy protocols for oral candidiasis in patients undergoing treatment for head and neck cancer: A two-arm, single-blind clinical trial. ⁶²	Fonseca LL...Guimaraes ALS	35772622	2022
44	The Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics in Oral Cancer Management. ⁶²	Mohd Fuad AS...Arzmi MH	36048406	2022
45	Autoimmune Polyglandular Syndrome Type 1: A Report of Rare Case of a 16-Year-Old Asian Female Patient With Respiratory Manifestations. ⁶²	Zainab K...Bisharat P	36072782	2022
46	Impact of Antiretroviral Therapy on Oral Health among Children Living with HIV: A Systematic Review and Meta-Analysis. ⁶²	Lam PPY...Wong HM	36231240	2022
47	Microplastic accumulation in the gastrointestinal tracts of nestling and adult migratory birds. ⁶²	Hoang TC...Mitten S	35577091	2022
48	Genotype-environment associations across spatial scales reveal the importance of putative adaptive genetic variation in divergence. ⁶²	Alvarado AH...Ruegg KC	36187181	2022
49	Thidiazuron, a phenyl-urea cytokinin, inhibits ergosterol synthesis and attenuates biofilm formation of Candida albicans. ⁶²	Harikrishnan P...Thirugnanasambantham K	36114903	2022
50	Challenge in the diagnosis, evaluation, and management of burning mouth sensation: A retrospective cohort study. ⁶²	Wu S...Yan Z	36167586	2022

Sources

Genes for Oral Candidiasis

Genes related to Oral Candidiasis (0 elite genes):

(show all 27)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	DEFB4A	Defensin Beta 4A	Protein Coding	20.43	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11936455 10225911
2	LTF	Lactotransferrin	Protein Coding	16.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15550920 12439202 11089630
3	SKAP2	Src Kinase Associated Phosphoprotein 2	Protein Coding	15.95	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11506465 15472333
4	HTN3	Histatin 3	Protein Coding	14.64	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12499171 11083633
5	IRF8	Interferon Regulatory Factor 8	Protein Coding	12.12	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
6	DEFA1	Defensin Alpha 1	Protein Coding	10.53	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	9.91	DISEASES inferred ¹⁴ ¹⁴
8	B2M	Beta-2-Microglobulin	Protein Coding	8.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7742405 7932082
9	CD4	CD4 Molecule	Protein Coding	8.16	DISEASES inferred ¹⁴
10	IKBKB	Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta	Protein Coding	7.55	GeneCards inferred via : Disorders (show sections)
11	DENND2B	DENN Domain Containing 2B	Protein Coding	7.09	DISEASES inferred ¹⁴
12	IL17A	Interleukin 17A	Protein Coding	6.92	DISEASES inferred ¹⁴
13	CARD9	Caspase Recruitment Domain Family Member 9	Protein Coding	6.92	DISEASES inferred ¹⁴
14	IL17RA	Interleukin 17 Receptor A	Protein Coding	6.91	DISEASES inferred ¹⁴
15	CLEC7A	C-Type Lectin Domain Containing 7A	Protein Coding	6.87	DISEASES inferred ¹⁴
16	APCS	Amyloid P Component, Serum	Protein Coding	6.87	GeneCards inferred via : Publications (show sections)
17	AIRE	Autoimmune Regulator	Protein Coding	6.76	DISEASES inferred ¹⁴
18	IL17F	Interleukin 17F	Protein Coding	6.66	DISEASES inferred ¹⁴
19	ECE1	Endothelin Converting Enzyme 1	Protein Coding	6.45	DISEASES inferred ¹⁴
20	CLEC6A	C-Type Lectin Domain Containing 6A	Protein Coding	6.44	DISEASES inferred ¹⁴
21	CD8A	CD8a Molecule	Protein Coding	6.43	DISEASES inferred ¹⁴
22	IL17RC	Interleukin 17 Receptor C	Protein Coding	6.35	DISEASES inferred ¹⁴
23	IL12RB1	Interleukin 12 Receptor Subunit Beta 1	Protein Coding	6.25	DISEASES inferred ¹⁴
24	DEFB103A	Defensin Beta 103A	Protein Coding	6.24	DISEASES inferred ¹⁴
25	DEFB103B	Defensin Beta 103B	Protein Coding	6.24	DISEASES inferred ¹⁴
26	GFM1	G Elongation Factor Mitochondrial 1	Protein Coding	6.21	DISEASES inferred ¹⁴
27	IL6	Interleukin 6	Protein Coding	6.11	DISEASES inferred ¹⁴

Sources

Variations for Oral Candidiasis

Sources

Expression for Oral Candidiasis

Search GEO for disease gene expression data for Oral Candidiasis.

Sources

Pathways for Oral Candidiasis

Pathways related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.1	IRF8 IL17RA IL17F IL17A IKBKB CD4
2	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.05	LTF IRF8 IL17RA IL17F IL17A IKBKB
3	NF-kappaB Signaling ³	12.28	B2M CARD9 IKBKB IL17A IRF8
4	CLEC7A (Dectin-1) signaling ⁶⁶ Show member pathways Alternative NF-kappaB pathway ⁶¹ CLEC7A/inflammasome pathway ⁶⁶ C-type lectin receptors (CLRs) ⁶⁶	12.23	IKBKB CLEC7A CLEC6A CARD9
5	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ⁶⁷ IL-17 signaling pathway ⁷⁴ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.05	IL17RA IL17F IL17A IKBKB
6	MAP kinase activation ⁶⁶ Show member pathways Interleukin-17 signaling ⁶⁶ MAP3K8 (TPL2)-dependent MAPK1/3 activation ⁶⁶	11.89	IL17RA IL17F IL17A IKBKB
7	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	11.77	IKBKB CD4 B2M
8	Defensins ⁶⁶ Show member pathways Alpha-defensins ⁶⁶ Antimicrobial peptides ⁶⁶ Beta defensins ⁶⁶ Ion influx/efflux at host-pathogen interface ⁶⁶ Metal sequestration by antimicrobial proteins ⁶⁶	11.74	LTF HTN3 DEFB4A DEFA1 CD4 CCR6
9	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.71	IL17F IL17A CD4
10	Innate Lymphoid Cells Differentiation ⁶⁵	11.59	IL17A CD4 CCR6
11	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.59	IL17RA IL17F IL17A IKBKB
12	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.54	IRF8 IL17RA CD4
13	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.52	IL17RA IL17F IL17A CD4
14	Th17 cell differentiation pathway ⁷⁴	11.3	IL17F IL17A IKBKB CD4
15	Endothelial cell senescence ⁷⁴	10.13	IL17RA IL17A

Sources

GO Terms for Oral Candidiasis

Cellular components related to Oral Candidiasis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	external side of plasma membrane	GO:0009897	9.4	IL17A ECE1 CLEC6A CD4 CCR6 B2M

Biological processes related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 28)

#	Name	GO ID	Score	Top Affiliating Genes
1	innate immune response	GO:0045087	10.39	APCS CARD9 CLEC6A CLEC7A IKBKB IL17A
2	adaptive immune response	GO:0002250	10.32	CARD9 CD4 CLEC6A IL17A IL17F IL17RA
3	immune response	GO:0006955	10.25	AIRE B2M CCR6 CD4 CLEC6A DEFA1
4	positive regulation of NF-kappaB transcription factor activity	GO:0051092	10.24	LTF IKBKB CLEC7A CARD9
5	defense response to Gram-positive bacterium	GO:0050830	10.24	IL17F IL17A DEFB4A DEFA1 CARD9
6	positive regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043123	10.23	CARD9 CD4 CLEC6A CLEC7A IKBKB LTF
7	defense response to bacterium	GO:0042742	10.21	LTF IRF8 HTN3 DEFB4A DEFA1
8	positive regulation of interleukin-6 production	GO:0032755	10.19	IL17RA IL17F IL17A CLEC7A CARD9
9	killing of cells of another organism	GO:0031640	10.11	DEFA1 DEFB4A HTN3 LTF
10	positive regulation of interleukin-12 production	GO:0032735	10.1	IRF8 IL17A CLEC7A
11	defense response to protozoan	GO:0042832	10.08	IRF8 DEFA1 CLEC7A
12	stimulatory C-type lectin receptor signaling pathway	GO:0002223	10.04	CLEC6A CLEC7A IKBKB
13	positive regulation of T-helper 17 type immune response	GO:2000318	10.03	CLEC7A CLEC6A CARD9
14	defense response to Gram-negative bacterium	GO:0050829	10.03	LTF IL17F IL17A DEFB4A DEFA1 CD4
15	interleukin-17-mediated signaling pathway	GO:0097400	10	IL17RA IL17F IL17A
16	antifungal innate immune response	GO:0061760	9.97	DEFB4A CLEC7A CLEC6A CARD9
17	response to yeast	GO:0001878	9.93	CLEC7A CLEC6A
18	negative regulation of viral process	GO:0048525	9.93	LTF APCS
19	fibroblast activation	GO:0072537	9.91	IL17RA IL17A
20	positive regulation of interleukin-23 production	GO:0032747	9.91	IL17RA IL17A CLEC7A
21	detection of yeast	GO:0001879	9.89	CLEC6A CLEC7A
22	positive regulation of antimicrobial peptide production	GO:0002225	9.88	IL17A IL17F
23	regulation of interleukin-2 production	GO:0032663	9.88	CARD9 IL17F
24	disruption of membrane integrity in another organism	GO:0051673	9.88	LTF DEFB4A DEFA1
25	positive regulation of chemokine (C-X-C motif) ligand 1 production	GO:2000340	9.88	IL17RA IL17F IL17A
26	positive regulation of cytokine production involved in inflammatory response	GO:1900017	9.85	CARD9 CLEC7A IL17A IL17F IL17RA
27	immune system process	GO:0002376	9.7	LTF IRF8 IL17RA IL17F IL17A CLEC7A
28	defense response to fungus	GO:0050832	9.4	IL17RA IL17A HTN3 DEFB4A DEFA1 CLEC6A